Purpose: Most tests developed for the determination of the HER2 status still require validation, although identification of the HER2 status is important for predicting the response to specific systemic therapy in breast cancer. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were performed for the HER2 expression on the tissue microarray (TMA) from primary breast cancers to validate the feasibility of IHC for HER2 assay. Methods: A TMA was constructed from 134 231 primary breast cancers. FISH and IHC were repeated more than twice, and the results were analyzed. Three kinds of primary antibody for IHC were used and compared. Results: The HER2 was amplified by FISH in 24 28% of breast cancer with a concordance between multiple assays of 92 100% (kappa=0.994-0.965), while the HER2 was overexpressed in 21 27% by IHC. The HER2 was amplified in 70 100% of the IHC 3+ cases, but was observed in only 45 78% and 5 12% of the IHC 2+ and IHC 0 1+ cases, respectively. The results from the IHC, using 3 different primary antibodies to HER2, were in good agreement each other at 88 92% (kappa=0.902-0.799).
